| Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers HA Yu, ME Arcila, N Rekhtman, CS Sima, MF Zakowski, W Pao, MG Kris, ... Clinical cancer research 19 (8), 2240-2247, 2013 | 2744 | 2013 |
| Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ... Cancer discovery 7 (6), 596-609, 2017 | 643 | 2017 |
| Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping PK Paik, A Drilon, PD Fan, H Yu, N Rekhtman, MS Ginsberg, L Borsu, ... Cancer discovery 5 (8), 842-849, 2015 | 642 | 2015 |
| Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer KC Arbour, E Jordan, HR Kim, J Dienstag, HA Yu, F Sanchez-Vega, P Lito, ... Clinical Cancer Research 24 (2), 334-340, 2018 | 454 | 2018 |
| EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes N Marcoux, SN Gettinger, G O’Kane, KC Arbour, JW Neal, H Husain, ... Journal of Clinical Oncology 37 (4), 278-285, 2019 | 425 | 2019 |
| Lineage plasticity in cancer: a shared pathway of therapeutic resistance Á Quintanal-Villalonga, JM Chan, HA Yu, D Pe’er, CL Sawyers, T Sen, ... Nature reviews Clinical oncology 17 (6), 360-371, 2020 | 415 | 2020 |
| Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim … LV Sequist, JY Han, MJ Ahn, BC Cho, H Yu, SW Kim, JCH Yang, JS Lee, ... The Lancet Oncology 21 (3), 373-386, 2020 | 396 | 2020 |
| Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses TK Sundaresan, LV Sequist, JV Heymach, GJ Riely, PA Jänne, WH Koch, ... Clinical Cancer Research 22 (5), 1103-1110, 2016 | 393 | 2016 |
| TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer GR Oxnard, JCH Yang, H Yu, SW Kim, H Saka, L Horn, K Goto, Y Ohe, ... Annals of Oncology 31 (4), 507-516, 2020 | 388 | 2020 |
| Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR … AY Helena, CS Sima, J Huang, SB Solomon, A Rimner, P Paik, ... Journal of Thoracic Oncology 8 (3), 346-351, 2013 | 374 | 2013 |
| Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib AJ Schoenfeld, KC Arbour, H Rizvi, AN Iqbal, SM Gadgeel, J Girshman, ... Annals of Oncology 30 (5), 839-844, 2019 | 373 | 2019 |
| Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers M Offin, H Rizvi, M Tenet, A Ni, F Sanchez-Vega, BT Li, A Drilon, MG Kris, ... Clinical Cancer Research 25 (3), 1063-1069, 2019 | 341 | 2019 |
| EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer K Hastings, HA Yu, W Wei, F Sanchez-Vega, M DeVeaux, J Choi, H Rizvi, ... Annals of Oncology 30 (8), 1311-1320, 2019 | 336 | 2019 |
| Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer AJ Schoenfeld, JM Chan, D Kubota, H Sato, H Rizvi, Y Daneshbod, ... Clinical Cancer Research 26 (11), 2654-2663, 2020 | 328 | 2020 |
| COVID-19 in patients with lung cancer J Luo, H Rizvi, IR Preeshagul, JV Egger, D Hoyos, C Bandlamudi, ... Annals of Oncology 31 (10), 1386-1396, 2020 | 324 | 2020 |
| Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes M Offin, JM Chan, M Tenet, HA Rizvi, R Shen, GJ Riely, N Rekhtman, ... Journal of Thoracic Oncology 14 (10), 1784-1793, 2019 | 323 | 2019 |
| 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial MJ Ahn, J Yang, H Yu, H Saka, S Ramalingam, K Goto, SW Kim, L Yang, ... Journal of Thoracic Oncology 11 (4), S115, 2016 | 290 | 2016 |
| Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain AY Helena, SK Tian, AE Drilon, L Borsu, GJ Riely, ME Arcila, M Ladanyi JAMA oncology 1 (7), 982-984, 2015 | 255 | 2015 |
| Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance HA Yu, K Suzawa, E Jordan, A Zehir, A Ni, R Kim, MG Kris, MD Hellmann, ... Clinical Cancer Research 24 (13), 3108-3118, 2018 | 249 | 2018 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 238 | 2020 |
